文献速递肿瘤 PET/CT核素与放射性配体治疗

德国PET显像利用现状与趋势:一项全面调查

PET imaging utilization and trends in Germany: a comprehensive survey.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-05-03

受德国核医学学会PET委员会委托,对德国PET中心进行综合调查,收集PET显像总量与适应证分组数据。2021年德国PET总量为154,400次(94%为PET/CT,6%为PET/MRI),按人口标化为每百万居民1,857次,低于法国(10,182次)、比利时(9,866次)和意大利(4,312次);2017年至2021年增长48%。前三位适应证领域为肿瘤(再)分期(76%)、诊疗一体化(13%)和神经病学(4%)。

要点

  • 2021年德国PET总量154,400次,其中PET/CT占94%、PET/MRI占6%。
  • 德国每百万居民PET显像1,857次,低于法国、比利时和意大利的公开数据。
  • 2017年至2021年德国PET量增长48%,作者观察到向诊疗一体化应用的明显转变。

核心结论

  • 德国PET显像的临床采用程度落后于意大利、法国和比利时。
  • 新建立的门诊报销制度似乎促进了近期PET量的增长。
  • 作者观察到向诊疗一体化应用的明显转变。

研究设计与样本

  • 受德国核医学学会PET委员会委托,对德国PET中心开展综合调查,收集PET显像数据,包括PET总量和适应证分组。

主要发现

  • 2021年德国全国PET总量为154,400次,其中PET/CT占94%、PET/MRI占6%。
  • 2021年按总人口标化的PET量在德国为每百万居民1,857次,法国为10,182次、比利时为9,866次、意大利为4,312次。
  • 2017年至2021年德国PET量显著增长48%。
  • 前三位适应证领域为肿瘤(再)分期76%、诊疗一体化13%、神经病学4%。
  • 前三位适应证为肺癌31%、前列腺癌16%、淋巴瘤/白血病12%;前三位放射性示踪剂为[18F]FDG 75%、PSMA放射性配体17%、生长抑素受体放射性配体8%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: PET imaging is a key diagnostic procedure in clinical routine worldwide. While public figures on PET volume are available in many countries, until now these numbers were not publicly known for Germany. METHODS: On behalf of the PET committee of the German Society of Nuclear Medicine, we conducted a comprehensive survey among PET centers in Germany to collect data on PET imaging, including the total PET volume and indication groups. RESULTS: National total PET volume in 2021 was 154,400 scans (94% PET/CT, 6% PET/MRI). PET volume in 2021 normalized to total population was lower in Germany (1,857 scans per 1 million inhabitants) when compared to public figures from France (10,182 scans), Belgium (9,866 scans), or Italy (4,312 scans). PET volume in Germany demonstrated significant growth 2017 to 2021 (+ 48%). Top three indication fields were oncological (re)staging (76%), theranostic (13%), and neurology (4%). The top three indications were lung cancer (31%), prostate cancer (16%), and lymphoma/leukemia (12%). The top three radiotracers used were [18F]FDG (75%), PSMA radioligands (17%), and somatostatin-receptor radioligands (8%). CONCLUSIONS: Clinical adoption of PET imaging in Germany is behind compared to Italy, France, and Belgium. However, newly established outpatient reimbursement seems to contribute to recent growth in PET volume. We observe considerable shift towards theranostic applications.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Holzgreve A, Hellwig D, Barthel H, et al. PET imaging utilization and trends in Germany: a comprehensive survey. Eur J Nucl Med Mol Imaging. 2025. PMID: 40317303. doi:10.1007/s00259-025-07323-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。